Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly (11C-PIB PET)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00811122|
Recruitment Status : Unknown
Verified June 2020 by University of Utah.
Recruitment status was: Active, not recruiting
First Posted : December 18, 2008
Last Update Posted : June 2, 2020
Alzheimer's disease (AD) is characterized by neuritic plaques, neurofibrillary tangles, and neuronal cell loss. Amyloid plaques are believed to play an integral role in AD. Elevated levels of Aβ in the brain are correlated with cognitive decline.
There are no approved ways to measure amyloid load in humans. Several compounds are under investigation. All of these compounds use radioactive chemical tags for positron emission tomography (PET) imaging. The most promising compound is 11C-PIB, or Pittsburgh Compound-B. This compound can be injected and a PET scan performed. This allows doctors to see the amyloid plaques in the brain, and to use this information to look at other types of dementia to see if there are differences and/or similarities in the plaques.
We will recruit a total of 30 subjects, 10 from each of the following three diagnostic categories: frontotemporal dementia (FTD), Alzheimer's disease, and normal volunteers. All subjects will be given an [18F]fluorodeoxyglucose or FDG-PET scan (if they haven't had one in the past) and a PIB-PET scan.
The overall objective of this project is to study the biodistribution of 11C-PIB using PET imaging in normal elderly volunteers and relevant patient groups.
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer's Disease||Radiation: 11C-PIB PET Scan Radiation: FDG-PET Scan||Early Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly|
|Study Start Date :||November 2009|
|Estimated Primary Completion Date :||April 2022|
|Estimated Study Completion Date :||April 2022|
- Radiation: 11C-PIB PET Scan
Participants will receive an 11C-PIB PET scan of the brain.Other Name: 11 Carbon Pittsburgh compound B
- Radiation: FDG-PET Scan
Participants will receive an FDG-PET scan of the brain.Other Name: 2-deoxy-2-[18F]fluoro-D-glucose (FDG)
- The agent 11C-PIB has similar biodistribution outside the brain in AD, FTD, and cognitively normal elderly individuals. [ Time Frame: 4 months ]
- Patients with AD scanned with 11C-PIB will have higher standardized uptake values (SUVs) than cognitively normal elderly in brain regions where beta amyloid are expected to be over-expressed. [ Time Frame: 4 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00811122
|United States, Utah|
|University of Utah|
|Salt Lake City, Utah, United States, 84112|
|Principal Investigator:||John M Hoffman, MD||Huntsman Cancer Institute/ University of Utah|